by Peter Ciszewski | Jun 23, 2017
The U.S. Food and Drug Administration today approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous administration to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients. The subcutaneous route of administration allows for...
by Peter Ciszewski | Jun 23, 2017
Lupus erythematosus is a name given to a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues.[1] Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood...
by Peter Ciszewski | Jun 22, 2017
The FDA granted orphan drug designation to Epizyme’s tazemetostat for the treatment of soft tissue sarcoma. Tazemetostat (Epizyme), a first-in-class EZH2 inhibitor, is being evaluated in an ongoing phase 2 study for the treatment of follicular lymphoma, diffuse...
by Peter Ciszewski | Jun 15, 2017
This educational video is produced by Fragile X Association and covers symptoms, diagnosis, and treatments of this rare disease.
by Peter Ciszewski | Jun 15, 2017
One in 20 women in the United Stares who were infected with Zika during pregnancy had babies with serious birth defects, according to the U.S. Centers for Disease Control and Prevention. The exact percentage of infants born with these Zika-linked defects depended on...
